Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine

Vaccine

Volumn 30, Issue 20, 2012, Pages 3090-3096

  Woolpert, Tabitha ^a   Staples, J Erin ^b   Faix, Dennis J ^a   Nett, Randall J ^b   Kosoy, Olga I ^b   Biggerstaff, Brad J ^b   Johnson, Barbara W ^b   Sracic, Michael ^c   Fischer, Marc ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c United States Marine Corps   (United States)

Author keywords

Immunization; Japanese encephalitis; Japanese encephalitis vaccines; Vaccines

Indexed keywords

INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE; MOUSE BRAIN DERIVED JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VERO CELL CULTURE DERIVED JAPANESE ENCEPHALITIS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; GEOMETRIC MEAN TITER; HEADACHE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; JAPANESE ENCEPHALITIS VIRUS; MAJOR CLINICAL STUDY; MALE; MYALGIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RASH; SEROPROTECTION; SOLDIER; VACCINATION; VERO CELL; VOMITING;

ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BRAIN; CERCOPITHECUS AETHIOPS; ENCEPHALITIS, JAPANESE; HUMANS; IMMUNIZATION, SECONDARY; JAPANESE ENCEPHALITIS VACCINES; MICE; MILITARY PERSONNEL; TECHNOLOGY, PHARMACEUTICAL; VACCINES, INACTIVATED; VERO CELLS;

EID: 84859423409     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.063     Document Type: Article

References (18)

1. World Health Organization Japanese encephalitis vaccines. Wkly Epidemiol Rec 2006, 81:331-340.
2. Centers for Disease Control and Prevention. Japanese encephalitis vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(RR-1):1-27.
3. Campbell G., Hills S., Fischer M., Jacobson J.A., Hoke C.H., Hombach J.M., et al. Estimated global frequency and incidence of Japanese encephalitis. Bull World Health Organ 2011, 89:766-774.
4. Hills S.L., Griggs A.C., Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg 2010, 82:930-936.
5. Food and Drug Administration Product approval information [package insert]. IXIARO (Japanese encephalitis vaccine, inactivated, absorbed). Livingston, United Kingdom; Intercell Biomedical.
6. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 2000, 18(Suppl. 2):26-32.
7. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23:5205-5211.
8. Centers for Disease Control and Prevention. Recommendations for use of a booster dose of inactivated Vero cell culture-derived Japanese encephalitis vaccine - Advisory Committee on Immunization Practices, 2011. MMWR Morb Mortal Wkly Rep 2011;60:661-3.
9. Centers for Disease Control and Prevention. Update on Japanese encephalitis vaccine for children - United States, May 2011. MMWR Morb Mortal Wkly Rep 2011;60:664-5.
10. Johnson B.W., Kosoy O., Hunsperger E., Beltran M., Delorey M., Guirakhoo F., et al. Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol 2009, 16:1052-1059.
11. Manly B. Randomization, bootstrap and Monte Carlo methods in biology 2001, Chapman & Hall/CRC, Boca Raton, FL. 2nd ed.
12. Rosenbaum P., Krieger A. Sensitivity of two-sample permutation inferences in observational studies. J Am Stat Assoc 1990, 85:493-498.
13. Chan I.S., Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 1999, 55:1202-1209.
14. Schuller E., Jilma B., Voicu V., Golor G., Kollaritsch H., Kaltenböck A., et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008, 26:4382-4386.
15. Dubischar-Kastner K., Eder S., Buerger V., Gartner-Woelfl G., Kaltenboeck A., Schuller E., et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 2010, 28:5197-5202.
16. ®, IC51. Vaccine 2011, 29:2607-2612.
17. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007, 370:1847-1853.
18. Tauber E., Kollaritsch H., von Sonnenburg F., Lademann M., Jilma B., Firbas C., et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008, 198:493-499.